The Endometrial Cancer Comprehensive Panel examines 11 genes associated with an increased risk for hereditary endometrial cancer.
Who is this test for?
Patients with a personal or family history suggestive of a hereditary endometrial cancer syndrome, which may include breast, colorectal, and other cancers. Red flags for hereditary endometrial cancer could also include onset of cancer prior to the age of 50 years, more than one primary cancer in a single person, and multiple affected people within a family. This test is designed to detect individuals with a germline pathogenic variant, and is not validated to detect mosaicism below the level of 20%. It should not be ordered on tumor tissue.
What are the potential benefits for my patient?
Patients identified with hereditary endometrial cancer can benefit from increased surveillance and preventative steps to better manage their risk for cancer. Also, your patient’s family members can be tested to help define their risk. If a pathogenic variant is identified in your patient, close relatives (children, siblings, parents) could have as high as a 50% risk to also be at increased risk.